These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 11241242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA, Montes Díaz MJ, Páez Borda A, Sánchez Sánchez E, Moreno Valle JA, Berenguer Sánchez A.
    Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
    [Abstract] [Full Text] [Related]

  • 3. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H.
    Prostate; 2003 Sep 15; 57(1):8-13. PubMed ID: 12886518
    [Abstract] [Full Text] [Related]

  • 4. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
    Cancer; 2005 Jan 15; 103(2):242-50. PubMed ID: 15578715
    [Abstract] [Full Text] [Related]

  • 5. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb 15; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 6. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK.
    J Urol; 2006 Apr 15; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [Abstract] [Full Text] [Related]

  • 7. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
    Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR.
    J Urol; 1997 May 15; 157(5):1740-3. PubMed ID: 9112517
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.
    J Med Assoc Thai; 2006 Jan 15; 89(1):37-42. PubMed ID: 16583579
    [Abstract] [Full Text] [Related]

  • 13. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Jan 15; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 14. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M, Okada K.
    Hinyokika Kiyo; 1993 Mar 15; 39(3):221-3. PubMed ID: 7685140
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 15; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Project Team.
    J Urol; 2005 Mar 15; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [Abstract] [Full Text] [Related]

  • 20. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ, Mangold LA, Epstein JI, Partin AW.
    Urology; 2004 May 15; 63(5):887-91. PubMed ID: 15134972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.